Carotid Artery Stenting With Cilostazol Addition for Restenosis

• Status: Completed
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

CAS-CARE study was conducted to evaluate the inhibitory effect of cilostazol, compared to that of other antiplatelet drugs, on in-stent restenosis following carotid artery stenting (CAS) in patients scheduled to undergo CAS. Study design is Multicenter Prospective Ranodomized Controlled Study, rondomized by cilostazol/non-cilostazol group prior to CAS. 900 patients will be enrolled for 2 years and followed 2 years with in-stent restenosis after CAS, evaluated by carotid ultrasound and angiography.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kobe City General Hospital
• Collaborators: Chiba University; Foundation for Biomedical Research and Innovation; Fukuoka University; Kobe University; Kyoto University; Mie University; Nagasaki University; Nagoya University; Okayama University; Osaka University; Wakayama Medical University; Yamaguchi University Hospital
• Treatments: Cilostazol; Platelet Aggregation Inhibitors

Criteria

Inclusion Criteria:

• 50% or more symptomatic carotid artery stenosis or 80% or more asymptomatic carotid artery stenosis

• scheduled for carotid artery stenting within 30 days

• 45 or more years-old and less than 80 years old

• antiplatelet agents can be administratered orally

• follow-up is anticipated possible for 2 years after CAS

• self-supporoted in daily activities (modified Rankin Scale 2 or less)

• patients who have given informed consent to participation in the study

Exclusion Criteria:

• received endovascular interevention

• scheduled for bilateral carotid intervention

• aortitis or cvasculitis

• congessive heart failure

• ischemic stroke within 48 hours

• hemorrhagic stroke within 90 days

• renal failure